Comparative in Vitro Activity of Zydotum against Gram Negative and Gram Positive Clinical Isolates

The present study was carried out to evaluate and compare the in vitro activity of BL BLI combinations containing sulbactam and tazobactam. Drugs evaluated include ceftazidime+sulbactam (Zydotum) ceftazidime+tazobactam (Combitaz), cefoperazone+sulbactam (Sulprazon), pipercillin+tazobactam (Tazocin) and ceftazidime (C-ZID) alone against gram-negative organisms obtained from different clinical specimens from different hospitals located in North and West region of India. Among 618 samples collected, 238 were sterile and only 380 samples showed the presence of bacterial infections with P. aerugenosa as the most predominant pathogen (56.3%) followed by E coli. (13.4%), S. aureus (10.8%), S. pneumoniae (9.2%,), P. vulgaris (4.7%), H. Influenzae (3.1%) and S. pyogenes (2.4%). Our results showed that the susceptibility of ceftazidime+sulbactam was the highest among all the isolated pathogen; P. aeruginosa (93.4%), E. coli (86.3%), H. influenzae (91.6%), P. vulgaris (83.3%), S. aureus (90.2%), S. pyogenes (88.8%) and S. pneumoniae (82.8%). Pipercillin+tazobactum was the second most effective drug against these gram negative and gram positive pathogens (66.8 to 77.7%), followed by ceftazidime+tazobactam (64.7 to 72.2%), cefoperazone+sulbactam (46.3-72.8%) and ceftazidime alone (25 to 28.6%). The results of the present study advocates the superiority of Zydotum over other tested antibiotics for the treatement of infections caused by ceftazidime resistant gram negative and positive bacteria.